Magenta Therapeutics is reducing the company’s workforce by 14 percent in a revised operating plan to prioritize research and development.
Cambridge-based Magenta Therapeutics entered a non-exclusive research and clinical collaboration agreement with Beam Therapeutics.
CRISPR Therapeutics and Vertex Pharmaceuticals announced positive interim data from the first patients in the companies’ Phase I/II clinical trials of the CRISPR/Cas9 gene-editing therapy CTX001.
Investor’s Business Daily looked at three small biotech companies that appear to be leading the CRISPR race.
